Commentary: How far would you go?

Christine E. Alvarado, MD, and Stephanie G. Worrell, MD, FACS

Esophagectomy with lymphadenectomy, plus or minus neoadjuvant chemoradiation, remains the standard of care for patients with localized esophageal cancer. Although current National Comprehensive Cancer Network Guidelines recommend a minimum of 15 lymph nodes (LN) be submitted for pathologic evaluation, questions regarding the location and extent of LN harvest persist.1

In this thoughtful discussion, Altorki2 proposes a new standardized nomenclature for esophageal cancer lymphadenectomy and considers the results of a randomized controlled trial by Li and colleagues3 from the Fudan University Group. That trial evaluated survival between 2- and 3-field LN dissection for cT1 through cT3/N0, N1 squamous cell carcinoma of the esophagus.3 Although results from the trial showed no difference in survival between the 2 groups, Altorki2 addresses important limitations. In particular, he highlights the significance of the nomenclature for lymphadenectomy used by Li and colleagues,3 arguing that their definition of 2-field lymphadenectomy, which included dissection of LNs along both recurrent laryngeal nerves (RLN), is actually an extended 2-field lymphadenectomy, which may account for the similarity in survival.

Because the majority of squamous cell carcinoma is located in the upper two-thirds of the esophagus, cervical and RLN nodes may be considered regional instead of distant metastases. Adenocarcinoma, the most common histologic subtype in the United States, predominantly occurs in the distal third of the esophagus, making the benefit of a more extensive nodal dissection less clear. Studies performed on junctional and Siewert type I cancers have shown metastatic rates >10% to the supracarinal LNs, but only 1% to 2% in Siewert type II cancers.4-6

Further complicating the need for extended lymphadenectomy is the use of neoadjuvant therapy. Since the publication of the Neoadjuvant Chemoradiotherapy Plus Surgery versus Surgery Alone for Oesophageal or Junctional Cancer (CROSS) trial, the majority of patients with esophageal cancer receive neoadjuvant chemoradiation.7,8 The patients in the CRO CROSS trial who received neoadjuvant therapy had significantly fewer LNs resected with no influence on survival with an extended lymphadenectomy. However, for patients who underwent surgery alone, there was a significant survival benefit to an extended lymphadenectomy.9 This continues to be an area of debate with other studies showing a benefit to lymphadenectomy postinduction therapy, although consistently less influential than in those who undergo surgery alone.10,11

In addition, implications regarding routine dissection of the RLN nodes are unknown. The Society of Thoracic Surgeons classifies RLN paresis as a major morbidity after esophagectomy.12 All patients in the Fudan trial underwent an open approach, which may have provided the ability to safely perform a 3-field dissection with lower risk of complications.3 However, with strong evidence showing the benefits of minimally invasive surgery, more esophagectomies within the United States are now being performed by a minimally invasive approach.13-15

From the Division of Thoracic and Esophageal Surgery, Department of Surgery, University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, Ohio.

Disclosures: The authors reported no conflicts of interest.
The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.

Received for publication June 25, 2021; revisions received June 25, 2021; accepted for publication June 25, 2021; available ahead of print July 1, 2021.

Address for reprints: Stephanie G. Worrell, MD, FACS, Department of Surgery and Division of Thoracic and Esophageal Surgery, University Hospitals Cleveland Medical Center and Case Western Reserve University, 11100 Euclid Ave, Cleveland, OH 44106 (E-mail: stephanie.worrell@uhhospitals.org).

J Thorac Cardiovasc Surg 2022;163:1698-9
0022-5223/$36.00
Copyright © 2021 by The American Association for Thoracic Surgery
https://doi.org/10.1016/j.jtcvs.2021.06.055

CENTRAL MESSAGE

Although a standardized nomenclature system for esophageal cancer nodal stations is necessary, the benefit of extended lymphadenectomy for esophageal adenocarcinoma is still unknown.
Adopting an extended lymphadenectomy in the era of minimally invasive surgery and neoadjuvant therapy may be hard for many to embrace. The community of surgeons treating esophageal cancer eagerly await the results of the Distribution of Lymph Node Metastases in Esophageal Carcinoma trial to help answer many of these questions. Until we have comparable data regarding histology and number and location of LNs resected in patients with and without induction therapy, these questions will remain unanswered.

References